Abstract:OBJECTIVES: MicroRNAs (miRNAs) were identified to be involved in various biological functions by regulating the degradation or suppressing the translation of their downstream target genes. Recent studies have identified miR-29a acts as tumor suppressor in hepatocellular carcinoma (HCC) progression. However, the underlying functions for miR-29a in HCC still to be investigated. METHODS: The expression of miR-29a expression in HCC tissues and corresponding adjacent normal tissues was detected using qRT-PCR analyses. Cell proliferation ability was assessed using CCK8 assay, cell colony forming and flow cytometry analysis. Bioinformatics, the dual luciferase reporter assay, qRT-PCR and western blot analysis were used to demonstrate that SIRT1 was a target of miR-29a. RESULTS: Here, we demonstrated that miR-29a was significantly downregulated in HCC tissues compared with corresponding adjacent normal tissues. Lower miR-29a expression associated with tumor size and vascular invasion of HCC. Furthermore, Lower miR-29a predicted a poor disease free survival (DFS) and overall survival (OS) time for HCC patients. Function assays showed that overexpression of miR-29a effectively suppressed cell proliferation, cell colony forming ability, and cell cycle progression. MiR-29a overexpression also inhibited the cell cycle related protein expression of CyclinD1 and CDK4, but increasing the P21 expression. Furthermore, Bioinformatics and the dual luciferase reporter assay analysis results demonstrated that miR29a specifically targeted the 3'-UTR of SIRT1 mRNA and regulated its protein expression. Increased SIRT1 expression rescued the inhibited effects induced by miR-29a overexpression in HCC cells. CONCLUSIONS: Thus, these results indicated that miR-29a may serve as a potential target of HCC treatment.

miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3

MicroRNA‐122 Suppresses Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma by Directly Targeting Wnt/β‐catenin Pathway

MicroRNA Let-7C Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma

MiR-148b Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma by Targeting WNT1/β-catenin Pathway

MicroRNA-302d Downregulates TGFBR2 Expression and Promotes Hepatocellular Carcinoma Growth and Invasion.

MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Mir-1299 Suppresses Cell Proliferation of Hepatocellular Carcinoma (hcc) by Targeting Cdk6

MiR-875-5p suppresses Gli1 to alter the hedgehog signaling pathway, which in turn has hepatocellular cancer-related tumor suppressing properties

MiR-29a Suppresses Cell Proliferation by Targeting SIRT1 in Hepatocellular Carcinoma

MiR-758-3p Suppresses Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells Via Targeting MDM2 and Mtor.

MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation.

miR-664b-5p Inhibits Hepatocellular Cancer Cell Proliferation Through Targeting Oncogene AKT2.

MicroRNA-212-3p Inhibits the Proliferation and Invasion of Human Hepatocellular Carcinoma Cells by Suppressing CTGF Expression

miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8

miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.

MicroRNA-520b Inhibits Growth of Hepatoma Cells by Targeting MEKK2 and Cyclin D1

MiR-511 Inhibits Growth and Metastasis of Human Hepatocellular Carcinoma Cells by Targeting PIK3R3

Mir-522 Contributes to Cell Proliferation of Hepatocellular Carcinoma by Targeting DKK1 and SFRP2

MicroRNA-1271-5p inhibits cell proliferation and enhances radiosensitivity by targeting CDK1 in hepatocellular carcinoma.

Down-regulation of MAP2K1 by Mir-539 Inhibits Hepatocarcinoma Progression.

MicroRNA-377-3p Promotes Cell Proliferation and Inhibits Cell Cycle Arrest and Cell Apoptosis in Hepatocellular Carcinoma by Affecting EGR1-mediated P53 Activation.